Previous 10 | Next 10 |
TCR2 Therapeutics (NASDAQ: TCRR ) announces positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 trial for mesothelin-expressing solid tumors. More news on: TCR2 Therapeutics Inc., Healthcare stocks news, Read more ... ...
- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients - Two RECIST unconfirmed partial responses and two patients with stable disease through six months - Manageable toxicity profile, with only one patient exhibiting TC-210-...
TCR 2 Therapeutics (NASDAQ: TCRR ) up 7.6% AH, in reaction to company's plans to discuss initial data from the Phase 1 portion of Phase 1/2 trial of its lead drug TC-210, in patients with mesothelin-expressing solid tumors, on Monday. More news on: TCR2 Therape...
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company plans to discuss initial data from the Pha...
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2...
CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced an expansion of its leadership team to strengthen e...
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will present an e-poster at the American As...
TCR2 Therapeutics (NASDAQ: TCRR ): Q1 GAAP EPS of -$0.65 beats by $0.76 . More news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Continued progress on treatment of TC-210 patients with interim update from Phase 1 portion of Phase 1/2 clinical trial anticipated in mid-2020 Continued progress of TC-110 with initiation of leading clinical sites participating in Phase 1/2 clinical trial that include Sarah Cannon Resea...
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Stephen Webster to its Board of ...
News, Short Squeeze, Breakout and More Instantly...
TCR2 Therapeutics Inc. Company Name:
TCRR Stock Symbol:
NASDAQ Market:
TCR2 Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (TCR 2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc....
NEW YORK, NY / ACCESSWIRE / March 30, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: U.S. Xpress Enterprises, Inc. (NYSE:...